Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered Prophages
PHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine.
Projectdetails
Introduction
Amid the antibiotic resistance crisis, the century-old practice of phage therapy, the use of bacterial viruses to treat bacterial infections, has gained renewed attention. Despite extensive research and clear-cut advantages over antibiotics, phage therapy has yet to gain momentum. This is primarily due to remaining limitations, e.g., the time-consuming process of identifying suitable phages and limited in vivo efficacy.
Proposed Technology
With PHAGE-PRO, I propose a new technology to overcome the shortcomings of traditional phage therapy. Unlike the conventional use of lytic phages, I will capitalize on prophages – viruses that integrate into bacterial genomes capable of excision and replication.
Benefits of Prophages
By integrating prophages into safe carrier strains, originating from probiotics, I will unlock two pivotal benefits:
- Rapid identification of suitable phages using advanced machine learning.
- Sustained in-vivo efficacy.
Yet, the core advantage of PHAGE-PRO lies in its unparalleled synergy of phage killing and pathogen competitive exclusion imposed by the probiotic.
Development Process
To realize this concept, the development of predictive tools is essential to quickly identify the most promising prophages and probiotic combinations for each pathogen (WP1).
Prophage Engineering
Prophage engineering (WP2), followed by rigorous in vitro testing, will ensure high safety and efficacy. High-throughput in vivo experiments using wax moth larvae will reveal the most promising candidate, which I will subsequently validate through a proof of principle experiment using a poultry model (WP3).
Broader Impact
Although I initially tailored PHAGE-PRO to treat Salmonella infections in poultry, its impact extends far beyond. This new technology holds the potential for transformative changes in phage therapy, not only advancing infection management in livestock farming through the enhancement of animal health and the assurance of food product safety, but also by opening the door for targeted preventive and therapeutic interventions in human medicine.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.500.000 |
Totale projectbegroting | € 1.500.000 |
Tijdlijn
Startdatum | 1-1-2025 |
Einddatum | 31-12-2029 |
Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHENpenvoerder
- HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Deciphering stringent response proteins and toxin-antitoxin systems in the arms race between bacteria and phagesThis project aims to identify phage proteins that target bacterial defense systems to advance phage therapy and improve bioremediation by studying Pseudomonas putida interactions. | ERC Starting... | € 1.499.250 | 2024 | Details |
Phage infection of bacterial biofilmThis project aims to characterize the dynamics of Herelleviridae phage phi812 in Staphylococcus aureus biofilms to enhance phage therapy effectiveness against antibiotic-resistant infections. | ERC Consolid... | € 1.992.976 | 2023 | Details |
In situ genetic perturbation of gut bacteria with engineered phage vectors and CRISPRThis project aims to develop synthetic biology tools for precise genetic manipulation of gut bacteria using phage vectors and CRISPR-Cas systems to enhance microbiome-targeted therapies. | ERC Consolid... | € 1.999.780 | 2022 | Details |
Breaking resistance of pathogenic bacteria by chemical dysregulationThe project aims to combat antibiotic-resistant bacteria by developing innovative small molecules that dysregulate bacterial physiology through a three-tiered chemical strategy. | ERC Advanced... | € 2.499.785 | 2023 | Details |
Exploring the Prokaryotic-Eukaryotic Conservation of Antiviral immunity: from bacterial immune systems to novel antiviral drugsThis project aims to map bacterial antiviral immunity and discover novel anti-phage compounds, potentially transforming our understanding of prokaryotic immune systems and leading to new antiviral therapies. | ERC Starting... | € 1.496.500 | 2022 | Details |
Deciphering stringent response proteins and toxin-antitoxin systems in the arms race between bacteria and phages
This project aims to identify phage proteins that target bacterial defense systems to advance phage therapy and improve bioremediation by studying Pseudomonas putida interactions.
Phage infection of bacterial biofilm
This project aims to characterize the dynamics of Herelleviridae phage phi812 in Staphylococcus aureus biofilms to enhance phage therapy effectiveness against antibiotic-resistant infections.
In situ genetic perturbation of gut bacteria with engineered phage vectors and CRISPR
This project aims to develop synthetic biology tools for precise genetic manipulation of gut bacteria using phage vectors and CRISPR-Cas systems to enhance microbiome-targeted therapies.
Breaking resistance of pathogenic bacteria by chemical dysregulation
The project aims to combat antibiotic-resistant bacteria by developing innovative small molecules that dysregulate bacterial physiology through a three-tiered chemical strategy.
Exploring the Prokaryotic-Eukaryotic Conservation of Antiviral immunity: from bacterial immune systems to novel antiviral drugs
This project aims to map bacterial antiviral immunity and discover novel anti-phage compounds, potentially transforming our understanding of prokaryotic immune systems and leading to new antiviral therapies.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
in silico bio-evolutio - novel AI paradigm for molecular biologyThis project aims to accelerate phage therapy by using an AI platform for in silico simulations to optimize phage selection, reducing experimental time and enhancing personalized treatment effectiveness. | EIC Accelerator | € 1.692.596 | 2023 | Details |
Fast, easy diagnostics for personalised phage therapyVésale Bioscience's Phagogram is an automated diagnostic tool that rapidly identifies effective bacteriophages for personalized phage therapy, reducing testing time from days to hours. | EIC Accelerator | € 1.800.000 | 2023 | Details |
InnomABsIPA onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten als alternatief voor antibiotica tegen antimicrobiële resistentie. | Mkb-innovati... | € 14.888 | 2023 | Details |
Targeted Nano-formulations for Treatment of MRSA: A multicomponent platform for nano-formulated treatment of resistant microbial infectionsLeadToTreat aims to develop targeted nano-formulations for treating MRSA infections by co-delivering novel low-drugability compounds and synergistic antibiotic combinations. | EIC Pathfinder | € 2.665.564 | 2022 | Details |
Pharmaco-modulation of epithelia for induction of antimicrobial peptide expression: a disruptive approach to fight antibiotic resistanceMaxImmun aims to develop innovative molecules that enhance antimicrobial peptides to combat infections and antibiotic resistance, progressing towards clinical trials. | EIC Pathfinder | € 3.194.450 | 2024 | Details |
in silico bio-evolutio - novel AI paradigm for molecular biology
This project aims to accelerate phage therapy by using an AI platform for in silico simulations to optimize phage selection, reducing experimental time and enhancing personalized treatment effectiveness.
Fast, easy diagnostics for personalised phage therapy
Vésale Bioscience's Phagogram is an automated diagnostic tool that rapidly identifies effective bacteriophages for personalized phage therapy, reducing testing time from days to hours.
InnomABs
IPA onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten als alternatief voor antibiotica tegen antimicrobiële resistentie.
Targeted Nano-formulations for Treatment of MRSA: A multicomponent platform for nano-formulated treatment of resistant microbial infections
LeadToTreat aims to develop targeted nano-formulations for treating MRSA infections by co-delivering novel low-drugability compounds and synergistic antibiotic combinations.
Pharmaco-modulation of epithelia for induction of antimicrobial peptide expression: a disruptive approach to fight antibiotic resistance
MaxImmun aims to develop innovative molecules that enhance antimicrobial peptides to combat infections and antibiotic resistance, progressing towards clinical trials.